Sleep and Insomnia: Comprehensive Notes (Transcript)

Overview

• Speaker's context: giving a sleep-focused CME talk early in the morning; acknowledges viewers across time zones; aims to improve patient communication about sleep.
• Career context: physician from Texas; has given seven years of talks on headaches; shifted toward sleep because sleep quality is crucial for headache management.
• Core message: to help patients sleep better, clinicians need the right tools and, above all, effective communication. Emphasis on non-pharmacological strategies as the primary tool, with medications used selectively.
• Learning objectives:
  • Describe how insomnia becomes and remains an issue using the 3P model (predisposing, precipitating, perpetuating).
  • Understand Process C (circadian) and Process S (sleep drive).
  • Outline the evidence base for non-pharmacological and pharmacological sleep therapies, including when medications may be appropriate.
• Foundational ideas and quotes:
  • Marcus Aurelius: everything that happens happens as it should; prompts questions about why sleep problems occur and whether the barrier is physical, environmental, or behavioral.
  • William James: the as-if principle; act as if you already have the sleep health you want by changing questions and behavior.
  • Concept: when you use a medication to do something the body naturally does, the body may forget how to do it on its own.
• Audience engagement: uses an audience-response system; examples and practical demonstrations integrated into the talk.
• Influential figures in sleep: Andrew Huberman (Stanford neuroscientist) and Peter Attia (longevity physician) cited as sources for sleep optimization ideas; Huberman’s sleep-focused content is recommended for patients.
• Practical emphasis: emphasize behavior change, sleep hygiene, and CBT for insomnia (CBTI) as first-line; medications as adjuncts, with clear cautions about risks and dependence.

The Two-Process Model of Sleep: Process S and Process C

• Core idea: sleep is governed by two interacting processes:
  • Process S (sleep drive): homeostatic sleep pressure that builds with wake time; strongest when you have been awake longer; linked to adenosine accumulation.
  • Process C (circadian rhythm): the brain’s internal clock that governs timing of sleepiness and wakefulness, aligned with the light-dark cycle.
• How Process S works:
  • Sleep drive is typically lowest at wake-up (morning) and increases throughout the day, peaking around ~23:00 (11 PM).
  • Adenosine binding to receptors promotes sleepiness; caffeine blocks adenosine receptors, delaying sleep and causing a crash when caffeine wears off.
• How Process C works:
  • Circadian alertness is lowest in the early morning, builds through the day, peaks in mid-afternoon, then declines toward evening.
  • Circadian rhythm times sleep by coordinating the light-dark cycle; melatonin release and cortisol rhythms are part of this coordination.
• Interaction and sleep gate:
  • The strongest sleep propensity occurs when there is a large separation between S and C (greatest delta between sleep drive and circadian alertness), allowing sleep to begin.
  • If S and C are not well matched, sleep maintenance and initiation can be disrupted (e.g., sleep onset at 11 PM but waking early at 7 AM due to a misaligned S/C profile).
• Visual representation (conceptual):
  • At ~7:00, both drives are low; S builds through the day; C rises and falls with the day; a large S–C delta around bedtime facilitates sleep initiation.
• Clinical implication:
  • To treat insomnia, consider whether the problem is primarily a mismatch in Process S or Process C and tailor interventions accordingly (e.g., light therapy to advance/adjust C or CBTI/behavioral changes to modify S).

Insomnia: Definitions, Prevalence, and Types

• Classic insomnia definition: difficulty with sleep initiation, sleep duration, sleep maintenance, or sleep quality, with associated daytime impairment.
• Prevalence and burden:
  • About 30% of the general population experiences insomnia at any given time.
  • About 50% of primary care patients have insomnia symptoms.
  • Approximately 75 million Americans report occasional insomnia; about 25 million have chronic insomnia.
  • A large majority do not discuss sleep complaints with clinicians (only about one third discuss; roughly 5% seek treatment).
• Types of insomnia are numerous; the talk does not enumerate every subtype but references a set of classifications and literature.
• Three-P Model (3P):
  • Predisposing factors: inherent vulnerabilities that increase susceptibility (e.g., a brain more alert to environmental cues; heightened circadian alertness).
  • Precipitating factors: events that trigger insomnia (e.g., death in the family, job loss, divorce; acute stress and anxiety).
  • Perpetuating factors: behaviors and patterns that sustain insomnia (e.g., excessive time in bed, poor sleep hygiene, maladaptive sleep habits such as napping).
• Clinical framing: when evaluating insomnia, determine whether sleep difficulties stem from S vs C, and how 3P factors may feed into the problem.

Sleep History and Assessment: How to Evaluate Sleep Complaints

• Sleep history questions (to elicit comprehensive information):
  • Sleep initiation, maintenance, duration, and quality; daytime impairment.
  • Comorbid medical and psychiatric conditions (depression, anxiety, other sleep disorders).
  • Medication history and prior sleep therapies.
  • Chronotype (early bird vs night owl) and shift-work history.
  • Lifetime sleep patterns and history of rested sleep when unconstrained.
  • Hypothetical ideal sleep pattern and what the patient would want their sleep to look like.
• Why self-report can be unreliable:
  • Sleepiness and impairment assessments can be biased; people may underestimate sleepiness or misjudge sleep duration.
  • Example: anesthesia residents on rounds could only accurately report sleep onset about half the time; obstructive sleep apnea patients often underestimate subjective sleepiness.
• Questionnaires and screening tools (with examples):
  • Insomnia Severity Index (ISI): 7 items over 2 weeks; assesses difficulty falling asleep, sleep maintenance, daytime impact, satisfaction.
  • Pittsburgh Sleep Quality Index (PSQI): broad assessment of sleep quality and disturbances over a month.
  • Epworth Sleepiness Scale (ESS): daytime sleepiness across daily situations.
  • STOP-BANG: screening for obstructive sleep apnea risk (snoring, tiredness, observed apnea, blood pressure, BMI, age, neck circumference, gender).
  • National Sleep Foundation sleep diary: 2 weeks of tracking caffeine, alcohol, bedtimes, bed in time, naps; useful for pattern detection.
• Case framing and interpretation:
  • Use sleep diaries and questionnaires to quantify sleep problems and guide CBT-I or pharmacological decisions.
• Practical point: patients may have untreated sleep apnea even if they don’t report daytime sleepiness; screening is important.

Case Illustrations: Pat and Chris (Two-Process Model in Action)

• Pat: falls asleep around 11 PM, wakes at 2 AM, returns to sleep by ~4 AM, and wakes at 7 AM.
  • Interpretation: robust Process S (strong sleep drive) but early-morning wakefulness due to an elevated circadian alertness (Process C) in the early morning; the mismatch favors delayed circadian signaling in the morning.
  • Intervention implication: align circadian timing (C) to promote earlier or more stable waketime; consider light exposure and melatonin timing.
• Chris: falls asleep around 11 PM but wakes at midnight; takes ~2 hours to fall back asleep; wakes around 6 AM.
  • Interpretation: insufficient sleep drive or poor consolidation (S) with early morning awakening; difficulty maintaining sleep due to a fall in S or a disrupted sleep cycle.
  • Intervention implication: enhance sleep drive before bedtime (CBT-I, schedule consistency) and consider interventions to improve sleep maintenance.
• Takeaway: use the two-process framework to tailor interventions (e.g., bright light therapy for circadian alignment; CBT-I for sleep drive consolidation; melatonin strategies for circadian timing).

Non-Pharmacological Therapies: Core Toolkit

• CBT for Insomnia (CBT-I): the most effective long-term treatment; typically delivered over 2–8 weeks; often requires access to trained psychologists.
  • In primary care and nurse practitioner settings, a scalable approach is found in randomized trials; some patients remit or improve with CBT-I delivered in a primary care context or via internet-based programs.
  • Key components of CBT-I include sleep restriction, stimulus control, sleep hygiene, relaxation techniques, and cognitive restructuring.
  • Official guidance: the American College of Physicians historically recommended CBT-I for adults with chronic insomnia.
• Sleep hygiene: basic guidelines (education) that are useful but not sufficient alone for sustained improvement; a supplement to other CBT-I strategies.
• Sleep restriction therapy (SRT): the most potent behavioral intervention in insomnia treatment; aims to increase sleep efficiency by restricting time in bed to match actual sleep time and gradually increasing it as sleep consolidates.
  • Mechanism: reduces time in bed spent awake, consolidates sleep, strengthens Process S, and improves sleep efficiency.
• Stimulus control: re-associate the bed with sleep and reduce wakeful activities in bed; restricts non-sleep activities to the bed; consistent wake times; no naps.
• Relaxation training: including progressive muscle relaxation, EMG biofeedback, autogenic training, self-hypnosis; used to calm arousal and reduce cognitive hyperarousal.
• Cognitive therapy: identifying and challenging irrational thoughts and catastrophic beliefs about sleep; replacing them with rational alternatives and coping strategies.
• Access and delivery considerations:
  • Access to CBT-I can be limited; the Royal Australian College of General Practice evaluated primary care delivery with positive outcomes (remission of insomnia in a subset; 60% response at 6 months; some patients referred to psychologists if non-responders).
  • Internet-based CBT-I resources exist (e.g., CBT-I Coach, Sleepio, Somn.i, Somerist); several are FDA-cleared or widely used in clinics.
  • Sleep diaries and paper handouts about sleep hygiene can be printed and given to patients as part of the training.
• Sleep hygiene printables and practical handouts:
  • Simple, patient-facing guidelines to improve routine, environment, and behavior around sleep; recommended as baseline education.
• Tools and apps for CBT-I and monitoring:
  • CBT-I Coach (VA-developed, free app): supports patient-guided CBT-I with clinician oversight.
  • SnoreLab: helps screen for suspected sleep apnea by analyzing nightly snoring data; if partner reports pauses in breathing, consider sleep study.
  • CBT resources: Greg Jacobs’ Say Goodnight to Insomnia (book/website); SleepRx; The Sleep Prescription (Mayo Clinic); The No More Sleepless Nights; Colleen Carney’s resources.
• Sleep-friendly behavioral adjustments and environmental tweaks:
  • Light exposure timing (bright light therapy) to entrain circadian rhythms.
  • Dark therapy: blue-light blocking glasses 1.5–3 hours before bedtime to reduce melanopsin stimulation and support sleep onset.
  • Light timing and chronotherapy considerations in bipolar disorder (see bipolar section below).
  • Exercise: regular activity supports sleep; timing matters (avoid excessive core body temperature rise close to bedtime).
• Tools for clinicians to manage patient expectations:
  • Emphasize that CBT-I and behavioral changes require practice and time; set realistic goals over 12–18 months; avoid harsh, short-term mandates.
  • Introduce the concept of a gradual, supported deprescribing of hypnotics with cross-titration to reduce rebound insomnia and dependence risks.

Light and Dark Therapies: Modulating Process C

• Bright light therapy for circadian entrainment (Process C):
  • Typical parameters: ~10,000 lux, vertically, about 1 meter away, for 30–90 minutes, preferably before 9:00 AM; some guidance suggests very bright light (up to ~100,000 lux) in the early morning light exposure window to set circadian timing.
  • Practical note: the goal is to advance or stabilize the circadian phase to reduce nighttime arousal and improve daytime alertness.
  • Applications: adjunct to depression treatment (sel at the onset of SSRI therapy); can enhance antidepressant response and sleep outcomes.
• Blue-light blocking and dark therapy: protecting Process C by limiting melanopsin stimulation in the evening (to promote melatonin release and sleep onset):
  • Use blue-blocking glasses about 1.5–3 hours before bedtime; not intended to increase sleepiness, but to preserve evening melatonin signal.
  • Clinical evidence: three randomized controlled trials show improved sleep regularity with blue-blocking lenses via effects on circadian alignment (Process C).
• Chronotherapy in bipolar disorder:
  • Bright light therapy can be used with caution in bipolar depression; generally shows no manic shift in most studies, but one study noted a small risk of hypomania in a subset of patients.
  • Dark therapy and chronotherapy approaches need careful consideration for bipolar patients due to cycling risks; mood stabilizers, timed light exposure, and close monitoring are advised.
• Practical tools and gadgets:
  • Somnilight blocks and UV-blocking lenses (examples cited): affordable options for blue-light blocking.
  • Sleep headphones and other wearable/sleep aids mentioned as convenience tools for relaxation and sleep routines.

Pharmacological Treatments: When and What to Consider

• General stance:
  • The speaker is cautious about medications; views them as supportive (“training wheels”) while patients learn to sleep naturally and implement CBT-I.
  • Emphasis on using medications only when necessary and for the shortest duration possible, with a plan to taper.
• Z-drugs (non-benzodiazepine GABA-A receptor agonists):
  • Efficacy timing: typically shorten sleep onset by about 11–33 minutes on average; around 22 minutes in some meta-analyses.
  • Cognitive/memory effects: animal studies show impaired memory encoding with hypnotics; human memory effects are a concern with these drugs.
  • Rebound insomnia and dependence: risk of withdrawal and rebound insomnia on cessation; potential daytime grogginess and cognitive impairment.
  • Mortality risk signal: large observational data show dose-dependent increases in all-cause mortality and cancer risk with hypnotics; approximate hazard ratios (HR) increase with dose categories:
  • HR ≈ 3.5 for 0.5–18 pills/year
  • HR ≈ 4.2 for 18–132 pills/year
  • HR ≈ 5.3 for >132 pills/year
• Benzodiazepines:
  • Similar concerns as Z-drugs; REM suppression and impact on sleep architecture; reduced slow-wave sleep with long-term use; dependence risk and rebound insomnia on discontinuation.
  • Short-acting benzodiazepines can be useful for sleep onset difficulties, but caution about dependence and the limited suitability for chronic insomnia.
• DORAs (dual orexin receptor antagonists):
  • Mechanism: target orexin (hypocretin) system to reduce wakefulness; aim to enhance sleep without broadly suppressing sleep architecture.
  • Efficacy: increase total sleep time; may improve REM sleep with limited effects on NREM sleep; early-generation agents include ciroxavant-like compounds (the transcript references a DORA named “ciroxavant”).
  • Clinical nuance: potential role for hyperarousal-related insomnia (e.g., PTSD) where calming wakefulness improves sleep onset.
• Melatonin and melatonin-related therapies:
  • Melatonin is particularly helpful for melatonin-deficient individuals, shift-work sleep disorder, and circadian misalignment; often used at low doses and timed well before sleep.
  • Dosing: typically around two hours before bedtime, on an empty stomach; generally no more than 5 mg.
  • Types: standard melatonin vs formulations designed for individuals with impaired melanopsin signaling or blindness; use depends on patient needs.
  • Interactions:
  • Beta-blockers can suppress endogenous melatonin; consider adding a small nightly melatonin dose when appropriate.
• Antidepressants and off-label agents:
  • Trazodone: commonly used off-label for sleep; potential to trigger migraines in some patients due to active metabolite; be cautious in headache patients.
  • Mirtazapine and amitriptyline: sometimes used for sleep due to sedative effects; watch for anticholinergic and other systemic effects.
  • Quetiapine/Olanazapine (antipsychotics): used off-label in certain psychiatric comorbidities; sedative effects may help sleep but carry metabolic and other risks.
  • Gabapentin and pregabalin: used off-label for sleep, anxiety, and neuropathic pain; may be helpful in specific populations (e.g., fibromyalgia, alcohol use disorder).
• Supplements and non-prescription options:
  • Magnesium (chelated forms such as magnesium threonate or glycinate) and L-theanine are commonly used supplements.
  • Apigenin and inositol may have a role in sleep and anxiety in some patients; evidence varies.
  • Tart cherry juice has been studied in geriatric populations for sleep benefits; data are mixed but some small trials show benefit.
• Practical takeaways for prescribing:
  • Consider non-pharmacologic strategies as first-line; medications may be used briefly while patients learn CBT-I and sleep-regulation strategies.
  • Be cautious about dependence, cognitive effects, and long-term risks—especially with sedative-hypnotics and benzodiazepines.
  • Involve discussions about risks of sleep medications for dementia and cognitive health; emphasize sleep health as a longevity issue.
• Special cases and cautions:
  • Bipolar disorder: avoid aggressive changes in sleep without mood stabilization; consider interpersonal and social rhythm therapy, chronotherapy, and motivational interviewing; ensure minimum 6.5 hours of sleep when possible; monitor for mania triggers with light exposure changes.
  • Perimenopause: sleep disturbances are common; relaxation training and breathing techniques can be helpful; consider targeted therapies for hot flashes or night awakenings; mindfulness-based approaches may be useful.
• Deprescribing guidelines and safety:
  • Alliance for Sleep Clinical Practice Guidelines for switching or deprescribing hypnotics are available as reference resources for clinicians.

Special Populations and Scenarios

• Bipolar disorder and sleep: special considerations due to circadian rhythm disruptions and risk of mania with certain chronotherapies; therapy focuses on stabilizing circadian rhythms and morning activity; avoid excessive sleep restriction; use light therapy with caution and under supervision.
• Autism spectrum disorders: sleep is often hyperaroused; adapt CBT-I strategies and behavioral routines; refer to autism-focused sleep resources; rely on established guidelines and therapy adaptations.
• Perimenopause: sleep disturbance is common; manage arousal and anxiety; consider non-pharmacologic approaches (relaxation, dark/light management) and judicious use of melatonin or other sleep aids as needed.
• Shift work sleep disorder: evaluate the potential role of melatonin, light exposure timing, and sleep scheduling; minimize circadian disruption when possible; prioritize consistent sleep-wake on days off when feasible.

Practical Clinical Strategies: Putting It All Together

• Screening and evaluation:
  • Screen all patients for sleep disorders; use ISI, PSQI, ESS, STOP-BANG and sleep diaries as appropriate.
  • Identify underlying psychiatric or medical issues that may contribute to insomnia; treat comorbid conditions as needed before CBT-I if possible.
• Treatment planning:
  • Start with non-pharmacological approaches: CBT-I, sleep hygiene, sleep restriction, stimulus control, relaxation training, and cognitive therapy.
  • When medications are considered, tailor to the individual’s presentation (latency vs maintenance problems, sleep architecture, comorbidities).
  • Consider light/dark therapies to optimize Process C and S balance; use bright light therapy for circadian entrainment and blue-blocking glasses for evening routines.
  • When starting medications, set clear goals, timelines, and a plan for tapering to avoid dependency and rebound insomnia.
• Patient education and motivation:
  • Communicate the health benefits of sleep and the risks of chronic poor sleep (e.g., potential dementia risk associated with poor sleep and sleep medications).
  • Use practical examples (e.g., the Reggie White example of severe sleep apnea and the fatal risks of untreated OSA) to illustrate consequences.
  • Encourage patients with a long-term plan (12–18 months) to achieve sustainable sleep health rather than quick fixes.
• Resources and tools for clinicians:
  • CBT-I websites and apps (Sleepio, Somerist, Restore, CBTI Coach).
  • SnoreLab for sleep apnea screening; use PSG (polysomnography) or home sleep apnea testing when indicated.
  • Sleep diaries and handouts for patients (printed materials and online resources).
  • Use of light therapy devices (10,000 lux bedside devices or morning bright light sessions) and blue-blocking glasses for evening use.
• Ethical and public health framing:
  • Emphasize the potential long-term health consequences of poor sleep and hypnotics; focus on empowering patients to change sleep behaviors rather than relying solely on medication.
  • Balance risks and benefits; acknowledge marketing pressures around sleep aids and the importance of evidence-based practice.
• Key takeaways you can apply now:
  • Screen routinely for insomnia and sleep apnea; use CBT-I as first-line treatment where possible.
  • Use sleep restriction and stimulus control to consolidate sleep; couple with relaxation and cognitive strategies for durable change.
  • Leverage light/dark therapy to align circadian timing; consider melatonin timing and exposure strategies.
  • Use pharmacology sparingly and with a clear taper plan; avoid long-term reliance on hypnotics; educate patients about potential risks and alternatives.

Quick Reference: Formulas, Timings, and Numbers (LaTeX)

• Two-process model basics:
  • Define sleep drive S(t) and circadian rhythm C(t).
  • Sleep propensity P_sleep(t) ∝ S(t) - C(t).
  • Sleep onset when S(t) - C(t) exceeds a threshold Δ^: P_{sleep}(t) ext{ increases when } S(t) - C(t) ightarrow ext{threshold } riangle^.
• Typical daily timing expectations (conceptual):
  • Sleep drive S(t) is lowest in the morning and peaks around $t ext{ ~ 23:00 (11 PM)}$.
  • Circadian alertness C(t) is lowest in the morning, builds through the day, peaks around $t ext{ ~ mid-afternoon}$, then declines.
• Epidemiology and risk figures (rounded):
  • Insomnia prevalence: about $30 ext{ ext{-}}50 ext{ ext{-}}75 ext{ million Americans}$ depending on the measure; chronic insomnia affects about $25 ext{ million}$.
  • CBT-I recommended as first-line for chronic insomnia by professional bodies; access remains a barrier in many settings.
  • Sleep and mortality/health signals:
  • Hypnotics risk: hazard ratios for mortality/cancer with Z-drugs and benzodiazepines rise with dose, e.g.,
    ext{HR}{0.5-18} \approx 3.5,\quad ext{HR}{18-132} \approx 4.2,\quad ext{HR}_{>132} \approx 5.3.\
  • Sleep health and mortality: a long-term study observed a reduction in all-cause mortality with low-risk sleep patterns by about $0.7\%$ and about $8\%$ of all-cause mortality risk attributable to suboptimal sleep patterns (relative to the studied cohort).
• Sleep duration target (general):
  • Aim for $7 ext{--} 8 ext{ hours}$ per night for optimal health.
• Melatonin timing and dosing:
  • Dose: up to $5 ext{ mg}$; administer about $2 ext{ hours}$ before bedtime on an empty stomach.
• Light therapy parameters:
  • Bright light therapy: $10{,}000 ext{ lux}$ for $30 ext{--} 90 ext{ minutes}$ before 9 AM.
  • Early morning light: exposure achieving high illuminance (~$100{,}000 ext{ lux}$) aids circadian entrainment.
• Z-drugs and sleep onset:
  • Typical reduction in sleep onset latency: approximately $11 ext{--}33 ext{ minutes}$; average around $22 ext{ minutes}$.
• Sleep restriction targets (example):
  • If ideal sleep is $8 ext{ hours}$ but current sleep is $5 ext{.5 hours}$, restrict time in bed to around $5.5 ext{ hours}$ and maintain a consistent wake time; progressively increase sleep opportunity as sleep consolidates.
• DORAs (ciroxavant-like):
  • Increase total sleep time and REM sleep without major disruption to non-REM sleep; clinical timing is individualized and used in targeted populations (e.g., hyperarousal).
• Commonly used sleep-related safety and screening tools (abbreviations):
  • ISI: Insomnia Severity Index; PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness Scale; STOP-BANG: sleep apnea risk screen.

References and Resources (Selected)

• CBT-I resources: SleepIO, Somerist, Restore, CBTI Coach (VA app), Greg Jacobs’ Say Goodnight to Insomnia, Colleen Carney’s materials.
• SnoreLab: screening for sleep apnea via nightly breathing analysis.
• Light/dark therapy devices and blue-light blocking glasses (e.g., sunglasses and specialized lenses).
• Foundational readings and authors referenced:
  • Huberman (Stanford) on sleep and neurobiology.
  • Peter Attia on longevity, sleep, and exercise as essential for healthspan.
  • Greg Jacobs’ CBT-I materials; Matt Walker’s explanations of sleep restriction.
  • The No More Sleepless Nights; The Sleep Prescription; The Sleep Doctor’s resources; The Sleep Coach materials.

Ethical and Practical Implications

• Sleep health is a foundational aspect of overall health, longevity, and cognitive function; poor sleep is linked to increased dementia risk and reduced quality of life.
• Clinicians should prioritize non-pharmacological therapies (CBT-I, behavioral modifications) as the foundation of insomnia treatment and reserve hypnotics for short-term, closely monitored use.
• Effective patient communication, realistic goal setting, and ongoing support are essential for long-term success; the process is a gradual journey rather than a quick fix.
• It’s essential to align treatment with the patient’s circadian biology, daily routines, and preferences to maximize adherence and outcomes.

Final Notes for Exam Preparation

• Be able to explain the 3P model and the 2-process model, including how Process S and Process C interact to regulate sleep, and how mismatches contribute to insomnia.
• Recall key prevalence data and the rationale for CBT-I as first-line therapy.
• Describe non-pharmacological strategies in detail (sleep restriction, stimulus control, CBT-I components) and how to apply them in cases like Pat and Chris.
• Know the main drug classes for sleep, their benefits, and especially the risks (memory effects, rebound insomnia, dependence, and mortality signals).
• Understand light and dark therapies, their practical parameters, and how they interact with circadian biology.
• Be able to discuss special populations (bipolar disorder, shift work, perimenopause, autism) and the tailored approaches needed.
• Be familiar with patient education resources and practical tools (CBT-I Coach, SnoreLab, Sleepdiaries) to implement sleep health in clinical practice.